Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.
Chih-Yi Liao, MD
Advertisement
Articles by Chih-Yi Liao, MD
Chih-Yi Liao, MD, discusses key considerations for the selection of single-agent vs combination regimens in frontline metastatic hepatocellular carcinoma.
Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5